Incorporate ethics approaches and use human values to guide innovation in research and technology for drug resistant epilepsy (DRE).
The current benchmarks never say the words "cure epilepsy". It is vaguely suggested by Area II, component E, but why be vague? We want to CURE EPILEPSY. Lets say that loud and clear, right?
Incorporate findings from the NINDS workshop entitled, "Metabolism-based Therapies for Epilepsy" (Nov 9. 2020)
One third of late-onset epilepsy have no known etiology. Cognitive symptoms are common with LOE and a third of these patients have mild cognitive impairment. Some patients with LOE have transient epileptic amnesia (TEA), while others develop neurodegenerative diseases such as Alzheimer's disease or dementia with Lewy bodies. Autoimmune causes have variable clinical presentations.